BridgeBio Pharma Price to Sales Ratio 2018-2024 | BBIO

Historical PS ratio values for BridgeBio Pharma (BBIO) over the last 10 years. The current P/S ratio for BridgeBio Pharma as of November 20, 2024 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
BridgeBio Pharma P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2024-11-20 23.04 18.91
2024-09-30 25.46 $1.22 20.90
2024-06-30 25.33 $1.23 20.62
2024-03-31 30.92 $1.23 25.19
2023-12-31 40.37 $0.06 696.58
2023-09-30 26.37 $0.06 440.12
2023-06-30 17.20 $0.04 463.00
2023-03-31 16.58 $0.53 31.30
2022-12-31 7.62 $0.53 14.40
2022-09-30 9.94 $0.61 16.40
2022-06-30 9.08 $0.62 14.65
2022-03-31 10.15 $0.48 20.93
2021-12-31 16.68 $0.48 34.99
2021-09-30 46.87 $0.39 120.65
2021-06-30 60.96 $0.44 138.15
2021-03-31 61.60 $0.07 842.20
2020-12-31 71.11 $0.07 1018.64
2020-09-30 37.52 $0.20 187.36
2020-06-30 32.61 $0.13 248.01
2020-03-31 29.00 $0.36 80.58
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.260B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00